Medistim (MEDI)

[TekBot]

First quarter results for 2023 for Medistim ASA

Medistim invites you to a presentation of the first quarter results for 2023 and status for the company. The first quarter results and preliminary financials will be presented through a webinar. The webinar takes place Tuesday the 25th of April and will start at 08.00 Norwegian time. The webinar will be available on Medistim website after the presentation.

Representatives for the company will be:
…

Vis børsmeldingen

Kari Eian Krogstad – CEO
Thomas Jakobsen - CFO

To sign up to join the webinar please follow the link to register:
https://bit.ly/Q1Results2023

Kilde

[TekBot]

Protocol from General Meeting in Medistim ASA

Attached is the protocol from the General Meeting in Medistim ASA
…

Vis børsmeldingen

Kilde

[TekBot]

The General Meeting in Medistim ASA decided a dividend of NOK 4.50 per share

Oslo, the 24th of April 2023. The votes from the General Meeting today in Medistim ASA, has resolved to distribute a dividend of NOK 4.50 per share based on the Company’s net profit for the 2022 financial year. The total dividend will amount to NOK 82.2 million, which corresponds to 72.1% of the net profit for 2022. The dividend will be payable to the shareholders of the Company as of the 24th of April 2023. The shares will be traded exclusive of the right to
dividends from and including the 25th of April 2023 (ex-date). The dividend will
be distributed the 5th of May 2023.
…

Vis børsmeldingen

Kilde

[TekBot]

FIRST QUARTER FINANCIAL RESULTS 2023

Sales for the first quarter ended at MNOK 129.3 (MNOK 116.1), an increase of 11.3%. The Vascular business segment continues the positive development and grows at 21.5% in NOK, currency neutral 8.8% growth. The Imaging products grow at 9.4% in NOK with a currency neutral decline of 3.7%. Currency neutral growth of own products was 2.5%. Operating profit (EBIT) for the quarter ended at MNOK 33.5 (MNOK 33.4). Medistim establishes direct sales organizations in both Canada and China this quarter. Cash position is down MNOK 3.3 due to inventory build up and timing of sales for the quarter. The General Meeting decided a dividend of NOK 4.50 per share, a total dividend payment of MNOK 82.2
…

Vis børsmeldingen

Kilde

[TekBot]

Ex dividend NOK 4.50 today

The shares in Medistim ASA will be traded ex dividend NOK 4.50 as from today, 25.04.2023
…

Vis børsmeldingen

Kilde

[TekBot]

Notification of trade

President and CEO in Medistim ASA, Kari E. Krogstad, has sold 37,719 shares to Medistim’s largest shareholder Aeternum Capital AS, at 265.00 NOK per share. The sale is related to the CEO’s private economy and need to free up liquidity. After the sale, Kari E. Krogstad holds a total of 38,083 shares in Medistim and Aeternum Capital AS holds 1,900,219 Medistim shares, which represent 10.16 % of the total shares in Medistim.
…

Vis børsmeldingen

Kilde

[TekBot]

First half results 2023 for Medistim ASA

Medistim invites you to a presentation of the first half results 2023 and status for the company. The first half results will be presented through a webinar. The webinar takes place Thursday the 31st of August and will start at 08.00 Norwegian time. The webinar will be available on Medistim website after the presentation.

Representatives for the company will be:
…

Vis børsmeldingen

Kari Eian Krogstad – CEO
Thomas Jakobsen - CFO

To sign up to join the webinar please follow the link to register: https://bit.ly/Q2Results2023

Kilde

[TekBot]

SECOND QUARTER AND FIRST HALF FINANCIAL RESULTS 2023 FOR MEDISTIM ASA

Sales for the second quarter ended at MNOK 137.4 (MNOK 117.5), an increase of 16.9%. Sales for first half ended at MNOK 266.6 (MNOK 233.6), an increase of 14.1%.

Currency neutral sales of own products was up 4.0% for the quarter and 2.5% for the first half.
…

Vis børsmeldingen

Operating profit (EBIT) for the quarter is up 13.1% and ended at MNOK 42.2, an EBIT margin at 30.7% (MNOK 37.3 an EBIT margin at 31.8%). For the first half EBIT is up 6.9% and ended at MNOK 75.7 an EBIT margin at 32.6% for the first half (MNOK 70.8 an EBIT margin at 35.3%).

Medistim established direct sales organizations in both Canada and China in Q2 and continues to strengthen its organization worldwide.

Medistim announced its participation in a groundbreaking cardiac surgery trial dedicated to women, ROMA-W.

A dividend of NOK 4.50 per share, a total of MNOK 82.2, was paid 5th of May.

Kilde

[Savepig]

Voldsomt så denne krakker da

[OYV]

https://twitter.com/edd_invest/status/1699318806437363804?s=21&t=TYKpxAmJsfGQwuGrqQB-6g

Sannsynlig sammenheng

[Ravioli]

Det er en sværing som vil ut. Kanskje et kjøpsläge for oss andre … https://www.finansavisen.no/finans/2023/09/06/8034135/krise-for-aeternum-og-vegard-soraune-john-fredriksen-vil-ha-ut-alle-pengene

[Savepig]

Ai, det forklarer mye ja.

Spørsmålet er jo om dette gir en varig eller permanent nedprising av porteføljeselskapene. Er jo veldig lite omsetning i flere av dem

[h3nk1]

Om ikke de finner kjøpere utenfor børs blir det jo brutalt.

[TekBot]

Major shareholder disclosure in Medistim ASA by Danske Bank AS

We hereby declare that Danske Bank Group as of September 15 reached above 5% of threshold in Medistim ASA. Total aggregated holding is 920,412.00 corresponding to 5.01 % of the total voting rights. Ownership consist of: Danske Invest Engros corresponding to 0.19%, Danske Invest corresponding to 0.39%, Kapitalforeningen Danske Invest Institutional corresponding to 1.27%, Finnish Fund corresponding to 0.30%, SICAV corresponding to 1.62% and Danske Fund Norway corresponding to 1.24%.
…

Vis børsmeldingen

Kilde

[TheLion]

Tøff times…

[TekBot]

Third quarter results 2023 for Medistim ASA

Medistim invites you to a presentation of the third quarter results 2023 and status for the company. The third quarter results will be presented through a webinar. The webinar takes place Friday the 27th of October and will start at 08.00 Norwegian time. The webinar will be available on Medistim website after the presentation.

Representatives for the company will be:
…

Vis børsmeldingen

Kari Eian Krogstad – CEO
Thomas Jakobsen - CFO

To sign up to join the webinar please follow the link to register:
Webinar Registration - Zoom

Kilde

[TekBot]

THIRD QUARTER FINANCIAL RESULTS 2023 FOR MEDISTIM ASA

Sales for the third quarter ended at MNOK 124 (MNOK 117), an increase of 6.5%. Sales YTD September ended at MNOK 391 (MNOK 350), an increase of 11.6%. Currency neutral sales of own products was down 5.6% for the quarter and up 1.2% YTD September. Operating profit (EBIT) for the quarter ended at MNOK 34 giving a 27.0% EBIT margin (MNOK 34, a 29.2% margin). YTD September EBIT is up 4.2% and ended at MNOK 109, giving a 27.9% margin (MNOK 105, a 29.9% margin).

Regional performance varies widely this quarter: Currency neutral, AMERICAS sales is down 10% for the quarter due to fewer systems sold as capital related to the challenging macro-economy. EMEA delivers 32% growth for the quarter and 14% YTD. APAC is going through transition from distributor to direct sales channel in China, and is down 55% this quarter.
…

Vis børsmeldingen

Higher operating expenses is related to increased commercial activities and strengthening of the sales organizations in several countries, including the newly established direct sales organizations in Canada and China.

Kilde

[TekBot]

Medistim ASA - Disclosure of large shareholding and transactions by close associates

1,900,219 shares in Medistim ASA were today, 27 September 2023, resolved to be transferred from Aeternum Capital AS to Acapital MEDI HoldCo AS (“HoldCo”) by way of a capital contribution in-kind. Aeternum Capital AS is managed by Aeternum Management AS. HoldCo is a 100% owned subsidiary of Aeternum Capital AS. Consequently, no change of beneficial ownership to the shares in Medistim ASA occurs as a result of the transfer, only the direct holder of the shares.

Following the transfer, HoldCo holds 1,900,219 shares in Medistim ASA, equal to approx. 10.36% of the votes and share capital. Aeternum Capital AS holds no shares in Medistim ASA directly following the transfer. No other rights to shares in Medistim ASA are held by any of the above mentioned entities.
…

Vis børsmeldingen

Both Aeternum Capital AS and HoldCo are closely associated persons of Anthea Arff-Pettersen, board member and primary insider in Medistim ASA. Please see attached forms for further details.

This information is subject to the disclosure requirements pursuant to Article 19 of the EU Market Abuse Regulation and Sections 4-2, cf. 5-12 of the Norwegian Securities Trading Act.

Kilde

[TekBot]

Medistim is opening a direct sales office in Sweden

Oslo, October 31, 2023) Medistim ASA (OSE: MEDI) is a niche market leader in
ultrasound technology, headquartered in Oslo, Norway. The company develops and
commercializes medical equipment for use in Cardiac, Vascular, and Transplant
…

Vis børsmeldingen

surgery. Today, Medistim announce that they are expanding their market coverage
in Sweden by establishing a direct sales office, opening today. This move is part
of the company’s ongoing commitment to providing exceptional service to
customers as well as fulfilling the company’s global growth strategy.

The company is well positioned to continue its growth by further developing the conversion from devices with Transit Time Flow Measurement (TTFM) technology only, to devices combining TTFM and High-Frequency Ultrasound (HFUS). In addition, the company have established exclusive distribution agreement with the Austrian manufacturer Agency for Medical Innovations (A.M.I.) with their product portfolio in urology, coloproctology and urogynecology. Medistim already has the rights for A.M.I. products in Norway and Denmark. With a direct presence in these three countries, Medistim is positioned to build a broader, Scandinavian distribution business.

The new subsidiary, Medistim Sverige AB, is a subsidiary of Medistim Norge AS, and
will be managed by Ole Jørgen Robsrud, Managing Director for Norway and Denmark.

Medistim take the opportunity to acknowledge and appreciate the longstanding and
successful collaboration with Vingmed AB since 1994. Vingmed have established the Medistim brand from scratch to become the recognized standard of care in cardiac, vascular and transplant surgery in Sweden that it is today.

“We are excited to take this step forward with our direct sales in Sweden, strengthening our relationship with our customers and also opening up for building a stronger Scandinavian third-party distribution business,” says Medistim President and CEO Kari E. Krogstad.

About Medistim:
Medistim was established in 1984 and has a track record of profitable growth
over the past 20 years. The company is a pioneer within its segment and
continues to invest in new product development. Medistim has wholly owned
subsidiaries with sales organizations in the USA, Canada, China, Germany, the
UK, Spain, Denmark, Sweden and Norway, in addition to around 60 distributors in Europe, Asia, the Middle East, Africa, and South America.

For more information, visit the Medistim home page: www.medistim.com

For more information, contact:
President and CEO, Kari E. Krogstad, Medistim ASA
Tel: + 47 918 38 110
Email: kari.krogstad@medistim.com

CFO, Thomas Jakobsen, Medistim ASA
Tel: + 47 906 59 940
Email: thomas.jakobsen@medistim.com

Kilde

[TekBot]

Management in Medistim ASA purchases shares

Management in Medistim ASA has the 13th of November purchased shares form Medistim
ASA. This is part of the company long term incentive plan approved by the
general meeting the 24th of April 2023. Price per share was NOK 161,67. The
…

Vis børsmeldingen

following members of management has purchased shares:

VP sales APAC Roger Morberg purchased 3410 shares and has 16259 shares after the purchase.

Chief Business Development Officer Ole Arne Eiksund purchased 3410 shares and has 5872 shares after the purchase.

CEO in Medistim Norge AS Ole Jørgen Robsrud purchased 1237 shares and has 3442 shares after the purchase.

VP Marketing Hæge Wetterhus purchased 928 shares and has 1591 shares after the purchase.

VP Sales EMEA Stephanie Stenhagen purchased 247 shares and has 557 shares after the purchase.

VP Innovation Håkon Grøthe purchased 3410 shares and has 7821 shares after the purchase.

CFO Thomas Jakobsen purchased 4547 shares and has 30526 shares after the purchase.

Medistim ASA has sold 17189 shares and has 57843 own shares after the sale.

Kilde